Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

medtronic plc - MDT

MDT

Close Chg Chg %
93.22 -1.51 -1.61%

Closed Market

91.72

-1.51 (1.61%)

Volume: 6.96M

Last Updated:

Oct 29, 2025, 3:59 PM EDT

Trade Now

Company Overview: medtronic plc - MDT

MDT Key Data

Open

$92.76

 Day Range

91.38 - 92.81

52 Week Range

79.29 - 99.37

 Market Cap

$119.59B

Shares Outstanding

1.28B

 Public Float

1.28B

Beta

0.79

 Rev. Per Employee

N/A

P/E Ratio

25.74

 EPS

$3.64

Yield

302.48%

 Dividend

$0.71

EX-DIVIDEND DATE

Sep 26, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

6.40M

  

MDT Performance

1 Week
 
 -0.47%
 
1 Month
 
 -4.58%
 
3 Months
 
 4.35%
 
1 Year
 
 3.51%
 
5 Years
 
 -7.30%
 

MDT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 34
Full Ratings ➔

About medtronic plc - MDT

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

MDT At a Glance

Medtronic Plc
Parkmore Business Park West
Galway, Galway 2
Phone 353-1-438-1700 Revenue 33.54B
Industry Medical Specialties Net Income 4.66B
Sector Health Technology 2025 Sales Growth 3.624%
Fiscal Year-end 04 / 2026 Employees 95,000
View SEC Filings

MDT Valuation

P/E Current 25.741
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.286
Price to Sales Ratio 3.237
Price to Book Ratio 2.247
Price to Cash Flow Ratio 15.41
Enterprise Value to EBITDA 14.298
Enterprise Value to Sales 3.86
Total Debt to Enterprise Value 0.229

MDT Efficiency

Revenue/Employee 353,021.053
Income Per Employee 49,073.684
Receivables Turnover 5.148
Total Asset Turnover 0.369

MDT Liquidity

Current Ratio 1.849
Quick Ratio 1.424
Cash Ratio 0.696

MDT Profitability

Gross Margin 59.785
Operating Margin 18.466
Pretax Margin 16.781
Net Margin 13.901
Return on Assets 5.133
Return on Equity 9.491
Return on Total Capital 6.004
Return on Invested Capital 6.234

MDT Capital Structure

Total Debt to Total Equity 61.69
Total Debt to Total Capital 38.153
Total Debt to Total Assets 32.315
Long-Term Debt to Equity 55.306
Long-Term Debt to Total Capital 34.205
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medtronic Plc - MDT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
31.69B 31.23B 32.36B 33.54B
Sales Growth
+5.21% -1.45% +3.64% +3.62%
Cost of Goods Sold (COGS) incl D&A
11.76B 12.32B 12.91B 13.49B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.71B 2.70B 2.65B 2.86B
Depreciation
974.00M 999.00M 954.00M 1.05B
Amortization of Intangibles
1.73B 1.70B 1.69B 1.81B
COGS Growth
-3.10% +4.77% +4.77% +4.46%
Gross Income
19.92B 18.90B 19.45B 20.05B
Gross Income Growth
+10.82% -5.12% +2.90% +3.07%
Gross Profit Margin
+62.88% +60.54% +60.11% +59.78%
2022 2023 2024 2025 5-year trend
SG&A Expense
12.78B 12.94B 13.36B 13.57B
Research & Development
2.65B 2.70B 2.73B 2.73B
Other SG&A
10.13B 10.24B 10.62B 10.84B
SGA Growth
+2.69% +1.24% +3.24% +1.60%
Other Operating Expense
956.00M 455.00M 364.00M 286.00M
Unusual Expense
596.00M 729.00M 1.03B 879.00M
EBIT after Unusual Expense
5.59B 4.78B 4.70B 5.31B
Non Operating Income/Expense
479.00M 1.17B 852.00M 1.04B
Non-Operating Interest Income
- 386.00M 597.00M 511.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
553.00M 583.00M 719.00M 729.00M
Interest Expense Growth
-10.37% +5.42% +23.33% +1.39%
Gross Interest Expense
553.00M 583.00M 719.00M 729.00M
Interest Capitalized
- - - -
-
Pretax Income
5.52B 5.36B 4.84B 5.63B
Pretax Income Growth
+41.64% -2.77% -9.82% +16.35%
Pretax Margin
+17.41% +17.18% +14.95% +16.78%
Income Tax
456.00M 1.58B 1.13B 936.00M
Income Tax - Current - Domestic
467.00M 1.30B 756.00M 583.00M
Income Tax - Current - Foreign
599.00M 530.00M 905.00M 692.00M
Income Tax - Deferred - Domestic
(402.00M) (336.00M) (435.00M) (322.00M)
Income Tax - Deferred - Foreign
(209.00M) 83.00M (93.00M) (17.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
5.06B 3.78B 3.70B 4.69B
Minority Interest Expense
22.00M 26.00M 28.00M 30.00M
Net Income
5.04B 3.76B 3.68B 4.66B
Net Income Growth
+39.77% -25.44% -2.18% +26.82%
Net Margin Growth
+15.91% +12.03% +11.36% +13.90%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
5.04B 3.76B 3.68B 4.66B
Preferred Dividends
- - - -
-
Net Income Available to Common
5.04B 3.76B 3.68B 4.66B
EPS (Basic)
3.7537 2.826 2.7687 3.6263
EPS (Basic) Growth
+40.00% -24.71% -2.03% +30.97%
Basic Shares Outstanding
1.34B 1.33B 1.33B 1.29B
EPS (Diluted)
3.7287 2.8196 2.7635 3.6142
EPS (Diluted) Growth
+40.01% -24.38% -1.99% +30.78%
Diluted Shares Outstanding
1.35B 1.33B 1.33B 1.29B
EBITDA
8.89B 8.21B 8.38B 9.05B
EBITDA Growth
+10.07% -7.72% +2.08% +8.06%
EBITDA Margin
+28.07% +26.28% +25.89% +27.00%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 100.932
Number of Ratings 34 Current Quarters Estimate 1.314
FY Report Date 10 / 2025 Current Year's Estimate 5.626
Last Quarter’s Earnings 1.26 Median PE on CY Estimate N/A
Year Ago Earnings 5.49 Next Fiscal Year Estimate 6.077
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 26 26 30 30
Mean Estimate 1.31 1.35 5.63 6.08
High Estimates 1.32 1.36 5.66 6.19
Low Estimate 1.31 1.32 5.60 6.00
Coefficient of Variance 0.36 0.68 0.24 0.77

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 12
OVERWEIGHT 4 4 5
HOLD 16 16 17
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Medtronic Plc - MDT

Date Name Shares Transaction Value
Jul 31, 2025 Denise L. Blomquist Chief Accounting Officer 12,425 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 31, 2025 Denise L. Blomquist Chief Accounting Officer 2,202 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 31, 2025 Denise L. Blomquist Chief Accounting Officer 1,278 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 2, 2025 Lidia L. Fonseca Director 5,891 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 495,079.64
May 2, 2025 Gregory P. Lewis Director 3,966 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 333,302.64
May 2, 2025 Elizabeth G. Nabel Director 17,615 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 1,490,229.00
May 2, 2025 Elizabeth G. Nabel Director 17,831 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 1,498,517.24
May 2, 2025 Gregory P. Lewis Director 3,785 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 320,211.00
May 2, 2025 Andrea J. Goldsmith Director 10,247 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 866,896.20
May 2, 2025 Andrea J. Goldsmith Director 10,463 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 879,310.52
May 2, 2025 Lidia L. Fonseca Director 5,675 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 480,105.00
May 2, 2025 Scott C. Donnelly Director 21,846 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 1,835,937.84
May 2, 2025 Kevin E. Lofton Director 8,171 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 691,266.60
May 2, 2025 Kevin E. Lofton Director 8,387 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 704,843.48
May 2, 2025 Craig Arnold Director 40,216 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 3,402,273.60
May 2, 2025 Craig Arnold Director 40,432 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 3,397,905.28
May 2, 2025 Randall J. Hogan Director 47,029 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 3,978,653.40
May 2, 2025 Randall J. Hogan Director 47,245 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 3,970,469.80
May 2, 2025 Kendall J. Powell Director 48,622 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $84.6 per share 4,113,421.20
May 2, 2025 Kendall J. Powell Director 48,838 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $84.04 per share 4,104,345.52

Medtronic Plc in the News